Comparison of Efficacy of Teriparatide (Parathyroid Hormone 1-34) Alone and in Combination with Zoledronic Acid for Osteoporosis in Postmenopausal Women.

Wei K, Qu Y, Gao Y, Ma Y

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP1 Feb 2021Cited by 3 (Europe PMC)

PMID33645201DOI10.29271/jcpsp.2021.02.240PepBankPUB-33645201

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, teriparatide plus zoledronic acid reduced VAS pain scores versus teriparatide alone after 6 months.
In plain wordsIn postmenopausal women with osteoporosis, teriparatide plus zoledronic acid reduced pain more than teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseVAS pain score
Study
n = 96
Comparator
Teriparatide alone
Outcome group
Pain · Musculoskeletal
Source sentences
Summary
After 6 months of treatment, VAS score, serum OPN and S-CTX levels in Group B were significantly lower than those in Group A (p=0.001, p<0.001 and p<0.001, respectively);
4 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this study was to compare the efficacy of teriparatide (parathyroid hormone 1-34) alone and in combination with zoledronic acid (ZA) for the treatment of osteoporosis in postmenopausal women.
Summary · context
Ninety-six patients were randomly equally divided into Groups A (n=48) and B (n=48).
Summary · context
Group A was given parathyroid hormone 1-34 alone.
Summary · context
Group B was treated with parathyroid hormone 1-34 plus ZA.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3364520101
02HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, teriparatide plus zoledronic acid reduced serum osteopontin versus teriparatide alone after 6 months.
In plain wordsIn postmenopausal women with osteoporosis, teriparatide plus zoledronic acid lowered serum osteopontin more than teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum osteopontin
Study
n = 96
Comparator
Teriparatide alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
After 6 months of treatment, VAS score, serum OPN and S-CTX levels in Group B were significantly lower than those in Group A (p=0.001, p<0.001 and p<0.001, respectively);
4 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this study was to compare the efficacy of teriparatide (parathyroid hormone 1-34) alone and in combination with zoledronic acid (ZA) for the treatment of osteoporosis in postmenopausal women.
Summary · context
Ninety-six patients were randomly equally divided into Groups A (n=48) and B (n=48).
Summary · context
Group A was given parathyroid hormone 1-34 alone.
Summary · context
Group B was treated with parathyroid hormone 1-34 plus ZA.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3364520102
03HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, teriparatide plus zoledronic acid reduced S-CTX versus teriparatide alone after 6 months.
In plain wordsIn postmenopausal women with osteoporosis, teriparatide plus zoledronic acid lowered S-CTX more than teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseSerum S-CTX
Study
n = 96
Comparator
Teriparatide alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
After 6 months of treatment, VAS score, serum OPN and S-CTX levels in Group B were significantly lower than those in Group A (p=0.001, p<0.001 and p<0.001, respectively);
4 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this study was to compare the efficacy of teriparatide (parathyroid hormone 1-34) alone and in combination with zoledronic acid (ZA) for the treatment of osteoporosis in postmenopausal women.
Summary · context
Ninety-six patients were randomly equally divided into Groups A (n=48) and B (n=48).
Summary · context
Group A was given parathyroid hormone 1-34 alone.
Summary · context
Group B was treated with parathyroid hormone 1-34 plus ZA.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3364520103
04HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, teriparatide plus zoledronic acid increased lumbar BMD versus teriparatide alone after 6 months.
In plain wordsIn postmenopausal women with osteoporosis, teriparatide plus zoledronic acid increased lumbar bone density more than teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar L2-4 BMD
Study
n = 96
Comparator
Teriparatide alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
and BMD values of lumbar vertebrae L2-4, femoral neck and total hip bone in Group B were higher than those of Group A (p=0.002, p=0.028 and p<0.001, respectively).
4 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this study was to compare the efficacy of teriparatide (parathyroid hormone 1-34) alone and in combination with zoledronic acid (ZA) for the treatment of osteoporosis in postmenopausal women.
Summary · context
Ninety-six patients were randomly equally divided into Groups A (n=48) and B (n=48).
Summary · context
Group A was given parathyroid hormone 1-34 alone.
Summary · context
Group B was treated with parathyroid hormone 1-34 plus ZA.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3364520104
05HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, teriparatide plus zoledronic acid increased femoral neck BMD versus teriparatide alone after 6 months.
In plain wordsIn postmenopausal women with osteoporosis, teriparatide plus zoledronic acid increased femoral neck bone density more than teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD
Study
n = 96
Comparator
Teriparatide alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
and BMD values of lumbar vertebrae L2-4, femoral neck and total hip bone in Group B were higher than those of Group A (p=0.002, p=0.028 and p<0.001, respectively).
4 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this study was to compare the efficacy of teriparatide (parathyroid hormone 1-34) alone and in combination with zoledronic acid (ZA) for the treatment of osteoporosis in postmenopausal women.
Summary · context
Ninety-six patients were randomly equally divided into Groups A (n=48) and B (n=48).
Summary · context
Group A was given parathyroid hormone 1-34 alone.
Summary · context
Group B was treated with parathyroid hormone 1-34 plus ZA.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3364520105
06HumanNot a test of Teriparatide (PTH 1-34) aloneRandomized controlled trialEfficacy outcome
In postmenopausal women with osteoporosis, teriparatide plus zoledronic acid increased total hip BMD versus teriparatide alone after 6 months.
In plain wordsIn postmenopausal women with osteoporosis, teriparatide plus zoledronic acid increased hip bone density more than teriparatide alone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTotal hip BMD
Study
n = 96
Comparator
Teriparatide alone
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
and BMD values of lumbar vertebrae L2-4, femoral neck and total hip bone in Group B were higher than those of Group A (p=0.002, p=0.028 and p<0.001, respectively).
4 context sentences(design, population, supporting numbers)
Summary · context
The purpose of this study was to compare the efficacy of teriparatide (parathyroid hormone 1-34) alone and in combination with zoledronic acid (ZA) for the treatment of osteoporosis in postmenopausal women.
Summary · context
Ninety-six patients were randomly equally divided into Groups A (n=48) and B (n=48).
Summary · context
Group A was given parathyroid hormone 1-34 alone.
Summary · context
Group B was treated with parathyroid hormone 1-34 plus ZA.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3364520106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.